AGM/EGMJun 10, 2026, 05:11 PM
Barinthus Biotherapeutics Announces 2026 Annual General Meeting
AI Summary
Barinthus Biotherapeutics plc has filed a definitive proxy statement (DEF 14A) announcing its 2026 Annual General Meeting (AGM) to be held on July 2, 2026. Key agenda items include the re-election of directors Karen T. Dawes and Anne M. Phillips, the re-appointment and ratification of PricewaterhouseCoopers LLP as auditors, and the receipt and advisory approval of financial reports and director compensation. The meeting will take place in London, with options for both ordinary shareholders and ADS holders to vote.
Key Highlights
- Barinthus Biotherapeutics plc to hold its 2026 Annual General Meeting on July 2, 2026, in London.
- Shareholders will vote on re-electing directors Karen T. Dawes and Anne M. Phillips.
- PricewaterhouseCoopers LLP proposed for re-appointment as U.K. statutory auditors.
- PricewaterhouseCoopers LLP proposed for ratification as independent registered public accounting firm for FY2026.
- Audit Committee to determine auditors' remuneration for FY2026.
- Shareholders to receive U.K. statutory annual accounts and reports for FY2025.
- Advisory vote on U.K. statutory directors' compensation report for FY2025.
Price Impact
More from BRNS